Initiative in LYon for Lung cAncer Screening Development - Prevalence Study

Lung Cancer Clinical Trial

— ILYAD1  

Official title:

Initiative in LYon for Lung cAncer Screening Development - Prevalence Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04240418
• Other study ID #: ILYAD1_2019
• Status: Completed
• Start date: October 31, 2020
• Est. completion date: January 14, 2021

Study information

• Verified date: July 2021
• Source: Hospices Civils de Lyon
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Screening at-risk subjects with low-dose computed tomography (CT) efficiently reduces lung cancer specific mortality. However screening efficiency relies on the at-risk population's criteria definition and its participation rate to the screening. In France, there are concerns regarding the participation rates to national cancer screening that are quite low (around 50% and 32% of the eligible population for breast cancer and colorectal cancer respectively). Before organizing national lung cancer screening it is then crucial to determine the factors impacting the at-risk subjects willingness to participate in lung cancer screening.

The Lyon University Hospital is the second biggest hospital in France with more than 23,000 employees distributed among more than 160 professions representing every level of education or working conditions. Its population is heterogeneous and wide enough to perform a prevalence study assessing the willingness to participate among the at-risk population.

ILYAD is a prospective study performed by anonymous questionnaires that will be submitted to the 23,000 employees of the Lyon University Hospital. The study main objective is to evaluate the at-risk population presence in the Lyon University Hospital population, as defined by NELSON criteria and selection criteria for lung cancer screening (PLCOm2012 scoring), and its willingness to participate to a lung-cancer screening with low-dose CT. This might help further efficient national lung cancer screening campaign organization.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 4595
• Est. completion date: January 14, 2021
• Est. primary completion date: January 14, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Aged = 18 years old

• Employee from the Lyon University Hospital (receiving salary from the Lyon University Hospital)

• Person who has willingness to respond the survey

Exclusion Criteria:

• Employees not hired by the Lyon University Hospital

• Employees who have not willingness to participate in the survey

Related Conditions & MeSH terms

• Lung Cancer
• Lung Neoplasms
• Screening

Intervention

Other:
• Survey
The objective is to evaluate the eligibility of the responders, as defined by NELSON criteria and PLCOm2012 scoring, and their willingness to participate to a lung-cancer screening with low-dose computed tomography.

Locations

Country	Name	City	State
France	Hospices Civils de Lyon	Lyon

Sponsors (1)

Lead Sponsor	Collaborator
Hospices Civils de Lyon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of employees belonging to the at-risk population for lung cancer and consequently eligible to lung cancer screening.	High-risk ever-smokers are defined as ever-smokers aged 55-74 years old, having smoked >15 cigarettes per day for >25 years or >10 cigarettes for >30 years and with =15 years since cessation for quitters.	Day 0 (at inclusion)